{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T06:46:37Z","timestamp":1648795597157},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,1,7]],"date-time":"2016-01-07T00:00:00Z","timestamp":1452124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,1,7]],"date-time":"2016-01-07T00:00:00Z","timestamp":1452124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1007\/s12029-015-9797-x","type":"journal-article","created":{"date-parts":[[2016,1,7]],"date-time":"2016-01-07T08:12:28Z","timestamp":1452154348000},"page":"66-69","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Capecitabine-Induced Severe Toxicity Secondary to DPD Deficiency and Successful Treatment with Low Dose 5-Fluorouracil"],"prefix":"10.1007","volume":"48","author":[{"given":"Saranya","family":"Kodali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Venu","family":"Bathini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Rava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eswar","family":"Tipirneni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,1,7]]},"reference":[{"key":"9797_CR1","unstructured":"Colorectal Cancer Screening and Surveillance\u2014American Family Physician. Accessed March 11, 2015. http:\/\/www.aafp.org\/afp\/2015\/0115\/p93.html."},{"issue":"7","key":"9797_CR2","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.ejca.2003.12.004","volume":"40","author":"ABP Van Kuilenburg","year":"2004","unstructured":"Van Kuilenburg ABP. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer. 2004;40(7):939\u201350. doi:10.1016\/j.ejca.2003.12.004.","journal-title":"Eur J Cancer"},{"issue":"6\u20137","key":"9797_CR3","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1080\/15257770802145009","volume":"27","author":"ABP Van Kuilenburg","year":"2008","unstructured":"Van Kuilenburg ABP, Maring JG, Schalhorn A, Terborg C, Schmalenberg H, Behnke D, et al. Pharmacokinetics of 5-fluorouracil in patients heterozygous for the IVS14\u2009+\u20091G> a mutation in the dihydropyrimidine dehydrogenase gene. Nucleosides Nucleotides Nucleic Acids. 2008;27(6\u20137):692\u20138. doi:10.1080\/15257770802145009.","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"3","key":"9797_CR4","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3816\/CCC.2004.n.018","volume":"4","author":"H Ezzeldin","year":"2004","unstructured":"Ezzeldin H, Diasio R. Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. Clin Colorectal Cancer. 2004;4(3):181\u20139. doi:10.3816\/CCC.2004.n.018.","journal-title":"Clin Colorectal Cancer"},{"issue":"6","key":"9797_CR5","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1111\/j.1365-2125.2008.03106.x","volume":"65","author":"H Blasco","year":"2008","unstructured":"Blasco H, Boisdron-Celle M, Bougnoux P, Gilles C, Tournamille J-F, Ciccolini J, et al. A well-tolerated 5-FU-based treatment subsequent to severe capecitabine-induced toxicity in a DPD-deficient patient. Br J Clin Pharmacol. 2008;65(6):966\u201370. doi:10.1111\/j.1365-2125.2008.03106.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"9797_CR6","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1007\/s00280-005-0139-8","volume":"58","author":"J Ciccolini","year":"2006","unstructured":"Ciccolini J, Mercier C, Dahan L, Evrard A, Boyer J-C, Richard K, et al. Toxic death-case after capecitabine\u2009+\u2009oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency. Cancer Chemother Pharmacol. 2006;58(2):272\u20135. doi:10.1007\/s00280-005-0139-8.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"9797_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/PL00008711","volume":"104","author":"ABP Van Kuilenburg","year":"1999","unstructured":"Van Kuilenburg ABP, Vreken P, Abeling NGGM, Bakker HD, Meinsma R, Van Lenthe H, et al. Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. Hum Genet. 1999;104(1):1\u20139. doi:10.1007\/PL00008711.","journal-title":"Hum Genet"},{"issue":"4","key":"9797_CR8","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3816\/CCC.2006.n.047","volume":"6","author":"C Mercier","year":"2006","unstructured":"Mercier C, Ciccolini J. Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil\/capecitabine therapy. Clin Colorectal Cancer. 2006;6(4):288\u201396. doi:10.3816\/CCC.2006.n.047.","journal-title":"Clin Colorectal Cancer"},{"issue":"12","key":"9797_CR9","first-page":"4705","volume":"6","author":"ABP van Kuilenburg","year":"2000","unstructured":"van Kuilenburg ABP, Haasjes J, Richel DJ, Zoetekouw L, Van Lenthe H, De Abreu RA, et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res. 2000;6(12):4705\u201312.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"9797_CR10","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.canlet.2006.09.006","volume":"249","author":"M Boisdron-Celle","year":"2007","unstructured":"Boisdron-Celle M, Remaud G, Traore S, Poirier AL, Gamelin L, Morel A, et al. 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer Lett. 2007;249(2):271\u201382. doi:10.1016\/j.canlet.2006.09.006.","journal-title":"Cancer Lett"},{"issue":"5","key":"9797_CR11","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s00280-011-1709-6","volume":"68","author":"E Giorgio","year":"2011","unstructured":"Giorgio E, Caroti C, Mattioli F, Uliana V, Parodi MI, D\u2019Amico M, et al. Severe fluoropyrimidine-related toxicity: clinical implications of DPYD analysis and UH2\/U ratio evaluation. Cancer Chemother Pharmacol. 2011;68(5):1355\u201361. doi:10.1007\/s00280-011-1709-6.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"9797_CR12","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1097\/01.ftd.0000245771.82720.c7","volume":"28","author":"J Ciccolini","year":"2006","unstructured":"Ciccolini J, Mercier C, Evrard A, Dahan L, Boyer J-C, Duffaud F, et al. A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy. Ther Drug Monit. 2006;28(5):678\u201385. doi:10.1097\/01.ftd.0000245771.82720.c7.","journal-title":"Ther Drug Monit"},{"key":"9797_CR13","unstructured":"National Guideline Clearinghouse\/Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Accessed March 11, 2015. http:\/\/www.guideline.gov\/content.aspx?id=47994."},{"issue":"5","key":"9797_CR14","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s11739-013-0936-8","volume":"8","author":"E Magnani","year":"2013","unstructured":"Magnani E, Farnetti E, Davide N, Casali B, Savoldi L, Focaccetti C, et al. Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase splice site variant: the need for further revision of dose and schedule. Intern Emerg Med. 2013;8(5):417\u201323. doi:10.1007\/s11739-013-0936-8.","journal-title":"Intern Emerg Med"},{"key":"9797_CR15","doi-asserted-by":"publisher","unstructured":"Deenen MJ, Meulendijks D, Cats A, Sechterberger MK, Severens JL, Boot H, et al. Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis. J Clin Oncol. 2015. doi:10.1200\/JCO.2015.63.1325.","DOI":"10.1200\/JCO.2015.63.1325"},{"issue":"10","key":"9797_CR16","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1097\/CAD.0000000000000133","volume":"25","author":"S Barni","year":"2014","unstructured":"Barni S, Ghidini A, Coinu A, Borgonovo K, Petrelli F. A systematic review of raltitrexed-based first-line chemotherapy in advanced colorectal cancer. Anticancer Drugs. 2014;25(10):1122\u20138. doi:10.1097\/CAD.0000000000000133. Review.","journal-title":"Anticancer Drugs"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-015-9797-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-015-9797-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-015-9797-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-015-9797-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T12:31:00Z","timestamp":1628598660000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-015-9797-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,7]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["9797"],"URL":"https:\/\/doi.org\/10.1007\/s12029-015-9797-x","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,7]]},"assertion":[{"value":"7 January 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}